Display options
Cite
Wehbi B, Pascal V, Zawil L, et al. History of IgA Nephropathy Mouse Models. J Clin Med. 2021;10(14)doi: 10.3390/jcm10143142.
Wehbi, B., Pascal, V., Zawil, L., Cogné, M., & Aldigier, J. C. (2021). History of IgA Nephropathy Mouse Models. Journal of clinical medicine, 10(14), . https://doi.org/10.3390/jcm10143142
Wehbi, Batoul, et al. "History of IgA Nephropathy Mouse Models." Journal of clinical medicine vol. 10,14 (2021). doi: https://doi.org/10.3390/jcm10143142
Wehbi B, Pascal V, Zawil L, Cogné M, Aldigier JC. History of IgA Nephropathy Mouse Models. J Clin Med. 2021 Jul 16;10(14). doi: 10.3390/jcm10143142. PMID: 34300307; PMCID: PMC8306110.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2021 Jul 16;10(14). doi: 10.3390/jcm10143142.

History of IgA Nephropathy Mouse Models.

Journal of clinical medicine

Batoul Wehbi, Virginie Pascal, Lina Zawil, Michel Cogné, Jean-Claude Aldigier

Affiliations

  1. Immunology Department, UMR CNRS 7276 INSERM 1262, Limoges University, 87032 Limoges, France.
  2. Immunology Department, EFS Bretagne, INSERM 1236, Rennes 1 University, 35000 Rennes, France.

PMID: 34300307 PMCID: PMC8306110 DOI: 10.3390/jcm10143142

Abstract

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world. It was first described in 1968 by Jean Berger and Nicole Hinglais as the presence of intercapillary deposits of IgA. Despite this simple description, patients with IgAN may present very broad clinical features ranging from the isolated presence of IgA in the mesangium without clinical or biological manifestations to rapidly progressive kidney failure. These features are associated with a variety of histological lesions, from the discrete thickening of the mesangial matrix to diffuse cell proliferation. Immunofluorescence on IgAN kidney specimens shows the isolated presence of IgA or its inconsistent association with IgG and complement components. This clinical heterogeneity of IgAN clearly echoes its complex and multifactorial pathophysiology in humans, inviting further analyses of its various aspects through the use of experimental models. Small-animal models of IgAN provide the most pertinent strategies for studying the multifactorial aspects of IgAN pathogenesis and progression. Although only primates have the IgA1 subclass, several murine models have been developed in which various aspects of immune responses are deregulated and which are useful in the understanding of IgAN physiopathology as well as in the assessment of IgAN therapeutic approaches. In this manuscript, we review all murine IgAN models developed since 1968 and discuss their remarkable contribution to understanding the disease.

Keywords: IgA; IgA nephropathy; kidney mesangium; mouse model

References

  1. Am J Pathol. 2007 Feb;170(2):447-56 - PubMed
  2. Food Chem Toxicol. 1989 Jun;27(6):361-8 - PubMed
  3. Clin Nephrol. 1990 Feb;33(2):72-86 - PubMed
  4. Am J Pathol. 2010 May;176(5):2188-97 - PubMed
  5. PLoS One. 2014 May 23;9(5):e98081 - PubMed
  6. Kidney Int. 2020 Feb;97(2):340-349 - PubMed
  7. Kidney Int. 2007 Jun;71(11):1148-54 - PubMed
  8. J Am Soc Nephrol. 2005 May;16(5):1289-99 - PubMed
  9. J Am Soc Nephrol. 2012 Aug;23(8):1364-74 - PubMed
  10. J Clin Lab Anal. 1990;4(2):115-9 - PubMed
  11. Nature. 2006 May 11;441(7090):235-8 - PubMed
  12. J Immunol. 2004 Jun 1;172(11):7177-85 - PubMed
  13. Clin Exp Nephrol. 2008 Feb;12(1):20-7 - PubMed
  14. PLoS One. 2016 Jul 20;11(7):e0159426 - PubMed
  15. Mucosal Immunol. 2014 Jul;7(4):948-57 - PubMed
  16. J Am Soc Nephrol. 2016 Sep;27(9):2748-61 - PubMed
  17. Kidney Int. 2009 Sep;76(5):546-56 - PubMed
  18. Annu Rev Pathol. 2013 Jan 24;8:217-40 - PubMed
  19. Semin Immunopathol. 2010 Jun;32(2):183-96 - PubMed
  20. J Am Soc Nephrol. 2020 Dec;31(12):2949-2963 - PubMed
  21. Clin Exp Immunol. 2001 Nov;126(2):326-33 - PubMed
  22. Nat Med. 1999 Sep;5(9):1018-25 - PubMed
  23. Nephrol Dial Transplant. 2008 Jun;23(6):1931-9 - PubMed
  24. Lab Invest. 1989 Apr;60(4):499-506 - PubMed
  25. Mol Cell Proteomics. 2014 Nov;13(11):3097-113 - PubMed
  26. J Clin Invest. 2004 Mar;113(6):826-35 - PubMed
  27. Nat Rev Nephrol. 2016 Mar;12(3):147-56 - PubMed
  28. Blood. 1999 Jun 15;93(12):4387-94 - PubMed
  29. Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1584-1586 - PubMed
  30. Cell Immunol. 2006 Jun;241(2):85-94 - PubMed
  31. J Exp Med. 2000 Jun 5;191(11):1999-2009 - PubMed
  32. J Clin Invest. 2008 Feb;118(2):629-39 - PubMed
  33. Kidney Int. 2003 Jun;63(6):2286-94 - PubMed
  34. Kidney Int. 1987 Dec;32(6):838-44 - PubMed
  35. J Am Soc Nephrol. 2008 May;19(5):1008-14 - PubMed
  36. J Pathol. 2021 Jun;254(2):159-172 - PubMed
  37. Immunity. 2018 Aug 21;49(2):211-224 - PubMed
  38. Med Sci (Paris). 2021 Jan;37(1):35-40 - PubMed
  39. Front Immunol. 2016 Apr 12;7:117 - PubMed
  40. Am J Pathol. 2010 Feb;176(2):608-18 - PubMed
  41. Kidney Int. 2018 Jun;93(6):1356-1366 - PubMed
  42. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3064-9 - PubMed
  43. Kidney Int. 1988 Feb;33(2):584-9 - PubMed
  44. Kidney Int. 1985 May;27(5):756-61 - PubMed
  45. Annu Rev Med. 2013;64:339-56 - PubMed
  46. J Exp Med. 2000 Jun 19;191(12):2171-82 - PubMed
  47. N Engl J Med. 2013 Jun 20;368(25):2402-14 - PubMed
  48. J Clin Invest. 2014 Jun;124(6):2325-32 - PubMed
  49. Kidney Int. 1996 Dec;50(6):1946-57 - PubMed
  50. Int Immunopharmacol. 2020 Dec;89(Pt B):107085 - PubMed
  51. Sci Transl Med. 2019 Aug 28;11(507): - PubMed
  52. J Exp Med. 2012 Apr 9;209(4):793-806 - PubMed
  53. J Am Soc Nephrol. 2019 Jul;30(7):1238-1249 - PubMed
  54. Nephrol Dial Transplant. 2019 Jul 1;34(7):1135-1144 - PubMed
  55. J Clin Invest. 2011 Oct;121(10):3991-4002 - PubMed
  56. J Am Soc Nephrol. 2021 Mar;32(3):545-552 - PubMed
  57. Kidney Int. 2015 Aug;88(2):276-85 - PubMed
  58. Kidney Int. 2017 Dec;92(6):1458-1468 - PubMed
  59. Am J Kidney Dis. 2015 Jan;65(1):80-7 - PubMed
  60. Nephron. 1988;49(2):104-6 - PubMed

Publication Types

Grant support